Warning Letters for CBD Products Making Fraudulent COVID-19 Claims - Drug Information Update

U.S. Food and Drug Administration sent this bulletin at 03/30/2022 12:58 PM EDT

If your email program has trouble displaying this email, view it as a web page.
FDA Center for Drug Evaluation and Research Division of Drug Information

Warning Letters for CBD Products Making Fraudulent COVID-19 Claims

As part of the FDA’s effort to protect consumers, the agency issued warning letters jointly with the Federal Trade Commission to seven companies for selling CBD products using research studies to claim or imply misleadingly that their CBD products will cure, mitigate, treat or prevent COVID-19. Consumers concerned about COVID-19 should consult with their health care provider. The companies that received warning letters are:


The FDA has not approved or authorized any drug containing CBD for the treatment or prevention of COVID-19. The agency is concerned these deceptive and misleading product claims could cause people to delay or stop appropriate medical treatment for COVID-19, leading to serious and life-threatening harm. Learn more about how to protect yourself from Fraudulent Coronavirus Tests, Vaccines and Treatments and report suspected health fraud.